AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00005622 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
Study NCT00005622 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
Study NCT02003612 — intervention group
Intervention type: OTHER
Intervention: Not applicable - observational study
Description: No intervention exists as this is a retrospective observational study
Study NCT04893603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve System
Description: Procedure: Transcatheter aortic valve replacement
Study NCT01238770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I.
Study NCT01426984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a capsule containing 20 mg
Study NCT01128348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient advocate
Description: patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
Study NCT01128348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient advocate
Description: patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
Study NCT00717522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT01069302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 600mg and maintenance 150mg for 7days
Study NCT01069302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 600mg and maintenance 75mg for 7days
Study NCT01069302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 300mg and maintenance 150mg for 7days
Study NCT01069302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading 300mg and maintenance 75mg for 7days
Study NCT01384500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline in tube cuff
Description: Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
Study NCT01620502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
Study NCT01620502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
Study NCT01620502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
Study NCT00387413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
Study NCT01577329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
Study NCT00387413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254
Description: Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
Study NCT00387413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189254 Placebo
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
Study NCT00387413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Placebo
Description: Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
Study NCT00486148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula (with GOS)
Description: Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
Study NCT01770626 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Nutrition
Description: Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
Study NCT01414907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion activities
Description: Counselled activities on tobacco smoking secession, diet correlation and physical activities
Study NCT01819077 — intervention group
Intervention type: PROCEDURE
Intervention: TMMR
Description: Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
Study NCT03103633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mean artery pressure
Description: mean artery pressure declined with less than 20% of baseline
Study NCT03103633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bispectral index
Description: BIS 45-60 before and after CPB; and BIS 40-45 during CPB
Study NCT03103633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain oxygen saturation
Description: Brain oxygen saturation declined with less than 20% of baseline
Study NCT03103633 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Controlled
Description: receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
Study NCT00735592 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Retrospective data obtained from electronic files
Study NCT03460665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography
Description: knee arteriography
Study NCT02826707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPPAC intervention
Description: A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
Study NCT03460665 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arteriography
Description: knee arteriography
Study NCT01725620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101 (Etanercept 25mg)
Study NCT01725620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel (Etanercept 25mg)
Study NCT04154020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexor tenotomy
Description: Tenotomy(cutting) of flexor tendons is performed with needle
Study NCT01304901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast 4 mg granule
Description: Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
Study NCT01304901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast placebo granüle
Description: Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
Study NCT02282020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLAPARIB
Description: 300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
Study NCT02282020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single agent chemotherapy
Description: Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study NCT01816633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoloGel
Description: AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
Study NCT02257788 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCR5
Study NCT02064894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral morphine and oral ibuprofen
Description: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
Study NCT04460391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive rehabilitation
Description: Early standing training and routine rehabilitation
Study NCT04460391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Description: Early standing training and routine rehabilitation
Study NCT02064894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral morphine
Description: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
Study NCT02064894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: oral ibuprofen combine to a placebo is the active comparator
Study NCT03542968 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: magnetic resonance imaging
Description: Acquisition 4D Flow magnetic resonance Imaging-8 minutes
Study NCT03542968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Acquisition 4D Flow magnetic resonance Imaging-8 minutes
Study NCT02329249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smokefree Partners: 21 Days to Freedom
Description: Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
Study NCT02329249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List Control
Description: Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
Study NCT02350725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide injection solution for subcutaneous administration (80 mg)
Study NCT02350725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Furosemide tablets (80 mg)
Study NCT00551733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00551733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00551733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00551733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Description: Given IV
Study NCT00293254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir potassium
Description: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
Study NCT00293254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
Study NCT03395886 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Description: The noninvasive ventilation intolerated patients was sedated by remifentanil.
Study NCT03395886 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
Study NCT02711540 — intervention group
Intervention type: PROCEDURE
Intervention: Balloon Aortic Valvuloplasty
Description: Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
Study NCT02450240 — intervention group
Intervention type: BEHAVIORAL
Intervention: standardized diagnostic assessment
Study NCT02510859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic nutritional consultation at home
Description: Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient.
Study NCT03483883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab IV 10 mg/kg every 2 weeks
Study NCT03483883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
Study NCT02184182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VLS ablation/portal ligation/hepatectomy
Description: Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy
Study NCT02452346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: 120 mg PO once daily continuously for each 28 day treatment cycle
Study NCT04384666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
Study NCT04384666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neupro 4 mg / 24 Hr. Transdermal Patch
Description: Neupro 4 mg /24 Hr. Transdermal Patch
Study NCT00475176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Study NCT00475176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT00475176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine for Chronic Liver Disease
Study NCT02178631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Online self-help
Study NCT02178631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as usual
Study NCT03804879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nidufexor
Description: 50 mg (two 25 mg) LMB763 capsules for oral administration
Study NCT02436668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Study NCT02436668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02436668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Study NCT02436668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT02436668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT05617053 — intervention group
Intervention type: DEVICE
Intervention: DAART
Study NCT05617053 — intervention group
Intervention type: DEVICE
Intervention: ATP/Supera stenting
Study NCT01897753 — intervention group
Intervention type: DRUG
Intervention: growth hormone
Description: 36 months
Study NCT02291757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEM brand eggshell membrane
Description: NEM 500 mg, once daily, p.o.
Study NCT02291757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 500 mg, once daily, p.o.
Study NCT02637427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma transfusion
Description: Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: Transrectal Ultrasound-Guided Biopsy
Description: Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: MRI Ultrasound Biopsy
Description: MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
Study NCT01838265 — intervention group
Intervention type: BEHAVIORAL
Intervention: Expanded Prostate Cancer index Composite Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
Study NCT01838265 — intervention group
Intervention type: BEHAVIORAL
Intervention: Short-Form 12 of Health Related Quality of Life Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
Study NCT03804879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration
Study NCT01838265 — intervention group
Intervention type: BEHAVIORAL
Intervention: Memorial Anxiety Scale for Prostate Cancer
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: Plasma/Serum Sample for biomarkers
Description: Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: Urine Sample for Biomarkers
Description: Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Tests for Blood Urea Nitrogen and Creatinine
Description: Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
Study NCT01838265 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Test for Serum PSA
Description: Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
Study NCT02310854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Repair
Description: augmented suture of acute ACL rupture (\<3 weeks after injury)
Study NCT02310854 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: reconstruction hamstring autograft
Study NCT03690492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Box 2.0
Description: Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
Study NCT01567501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Dihydrochloride tablets 5 mg
Description: 5 mg tablet once in a day
Study NCT01567501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Dihydrochloride
Description: 5 mg tablet once in a day
Study NCT01860157 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainsway H1-Coil Deep TMS System (Sham treatment)
Description: In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
Study NCT01860157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway H1-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions